• Home
  • About Us
G3P G3P
  • Home
  • About Us
  • G-3 Galectin
    G3 in our name stands for Galectin 3
    A remarkable and important protein.
  • G-3 Galectin
    Everyday a new paper is
    published about Galectin-3.
  • G-3 Galectin
    Countless papers characterize
    Galectin-3 as an important mediator of tissue damage
  • G-3 Galectin
    Our studies have investigated the role of pectins...

The work we started more than 15 years ago sparked scientific interest in galectin-3 around the world.

The insights it produced form the foundation of our company.

Galectin-3 Primer

Galectin-3  

..is a protein that regulates functions of other cells

..has a built-in “on-off” switch controlled by special carbohydrates

..is commonly the link between inflammation and cell injury and death

..promotes fibrosis in response to injury or inflammation

..was found to be essential in key disease pathways

..can be measured in blood

..appears to do more harm than good – animals without galectin-3 are healthy and can reproduce.

Researchers from Around the World Share Our View

  • The CT-1/Gal-3 axis emerges as a candidate therapeutic target and a potential prognostic biomarker in HF.
    Martínez-Martínez E
    Hypertension. 2019 Jan 7
    Country: Spain
  • “Gal-3 inhibition may represent a new promising therapeutic option in heart failure”
    Vegaro G
    Hypertension. 2016 Mar;67(3):606-12
    Country: France
    Access this Publications
  • “Thus, antagonistic stragtegies targeting Gal-3 may be a novel therapeutic approach in providing the cardiac protection in hypertension and heart failure”
    González GE
    Am J Physiol Heart Circ Physiol. 2016 Nov 1;311(5):H1287-H1296
    Country: USA
  • “These data suggest a key role for Gal-3 in cardiorenal remodeling and dysfunction induced by aldosterone. Gal-3 could be used as a new biotarget for specific pharmacological interventions.”
    Calvier L
    JACC Heart Fail. 2015 Jan;3(1):59-67
    Country: France
  • “Gal-3 pharmacological inhibition blocks aortic and aortic valve remodeling in experimental pressure overload. Gal-3 could be a new therapeutic approach to delay the progression and the development of aortic remodeling and aortic valve calcification in pressure overload.”
    Ibarrola J
    Int J Mol Sci. 2017 Jul 31;18(8). pii: E1664
    Country: Spain
    Access this Publication
  • “Collectively, our results suggest that galectin-3 may be an attractive target for the pre-vention and treatment of HF.”
    Yu L
    Circ Heart Fail. 2013 Jan;6(1):107-17
    Country: The Netherlands
    Access this Publication
  • “Targeting Gal-3 may be an upstream therapeutic option for the treatment of kidney damage that accompanied pathological conditions such as obesity and aortic stenosis.”
    Martinez-Martinez E
    PLoS One. 2016 Nov 9;11(11):e0166272
    Country: Spain
    Access this Publication
  • “Therefore, Gal-3 plays an important role in the PAH-induced right ventricular remodeling through interacting with the Nox4 and Nox4-derived oxidative stress. Gal-3 may become a RV-specific diagnostic and therapeutic target for clinics.”
    He J
    J Am Soc Hypertens. 2017 May;11(5):275-289.e2
    Country: China
  • “Moreover, by demonstrating Gal-3 expression in human hearts, our finding reinforces that this protein could be a novel target for drug development for Chagas cardiomyopathy.”
    Souza BSF
    Am J Pathol. 2017 May;187(5):1134-1146
    Country: Brazil
  • “In conclusion, Gal 3 serves a fundamental role in hypoxia induced PAH, and inhibition of Gal 3 may represent a novel therapeutic target for the treatment of hypoxia-induced PAH.”
    Hao M
    Mol Med Rep. 2017 Jan;15(1):160-168
    Country: China
  • “In obese animals, Gal-3 blockade decreases cardiovascular fibrosis and inflammation. These data suggest that Gal-3 could be a novel therapeutic target in cardiac fibrosis and inflammation associated with obesity.”
    Martínez-Martínez E
    Hypertension. 2015 Nov;66(5):961-9
    Country: Spain
    Access this Publication
  • “The lack of commercially available anti-Gal-3 therapeutic reagents and its clear involvement in serious disease, notably cancer, leads to an urgent need for development of inhibitors that specifically target Gal-3.”
    Blanchard H
    Expert Opin Ther Pat. 2014 Oct;24(10):1053-65
    Country: Australia
  • “The finding that galectin-3 is associated with the risk of developing HF following ACS adds to emerging evidence supporting galectin-3 as a biomarker of adverse remodeling contributing to HF as well as a potential therapeutic target.”
    Grandin EW
    Clin Chem. 2012 Jan;58(1):267-73
    Country: USA
    Access this Publication
  • “In conclusion, galectin-3 is an emerging all-out player in metabolic disorders and their complications that deserves further investigation as the potential target of therapeutic intervention.”
    Pugliese G
    Glycobiology. 2015 Feb;25(2):136-50
    Country: Italy
  • “Our results suggest a potential role for gal-3 in CAI, and this represents a potentially exciting therapeutic target.”
    Dang Z
    Transplantation. 2012 Mar 15;93(5):477-84
    Country: United Kingdom
  • “Inhibiting Gal-3 during AF progression might be useful as an adjuvant treatment to improve outcomes of catheter ablation for persistent AF. Gal-3 inhibition may be a potential new upstream therapy for prevention of AF progression.”
    Takemoto Y
    JACC Basic Transl Sci. 2016 Apr;1(3):143-154.
    Country: USA
    Access this Publication
  • “Our findings suggest that galectin-3 may detect kidney injury years before the clinical onset of CKD, potentially affording an opportunity to institute early, targeted treatment aimed at disease prevention.”
    O'Seaghdha CM
    J Am Soc Nephrol. 2013 Sep;24(9):1470-7
    Country: USA
    Access this Publication
  • “Animal data suggest that Gal-3 is a mediator of fibrosis, and directly targeting the Gal-3 pathway may represent a future preventive treatment strategy.”
    Ho JE
    J Am Coll Cardiol. 2012 Oct 2;60(14):1249-56
    Country: USA
    Access this Publication
  • “Gal-3 may be a clinically useful biomarker that identifies a subset of Kawasaki disease patients at highest risk of myocardial and vascular fibrosis, and may be an attractive therapeutic target to prevent myocardial dysfunction in this subset.”
    Numano F
    Int J Cardiol. 2015 Dec 15;201:429-37
    Country: USA
  • “In addition to its clinical utility in the differentiation of patients with HF to better match the level of care to individual needs, galectin-3 measurement should enable the study and development of the first generation of disease-modifying therapies to inhibit remodelling and halt or slow HF progression.”
    de Boer RA
    Eur J Heart Fail. 2009 Sep;11(9):811-7
    Country: The Netherlands
    Access this Publication
  • “Targeting Galectin-3 may be an upstream therapeutic option for the treatment of all types of heart failure.”
    Wu CK,
    Sci Rep. 2015 Nov 19;5:17007
    Country: Taiwan
    Access this Publication
  • “These results shape the concept of considering galectin-3 as a new target for therapeutic intervention at an early stage of compensated hypertrophy in failure-prone hearts.”
    Sharma UC
    Circulation. 2004 Nov 9;110(19):3121-8. Epub 2004 Nov 1.
    Country: The Netherlands
    Access this Publication
  • “This study suggests galectin-3 to be a novel therapeutic target against post-aneurysmal subarachnoid hemorrhage early brain injury."
    Nishikawa H
    Stroke. 2018 Nov;49(11):2743-2751.
    Country: Japan
  • “Our findings provide support for the role of inflammatory biomarkers in the pathogenesis of atherosclerosis and suggest galectin-3 as a possible target for intervention in the prevention or management of atherosclerotic disease.".
    Oyenuga A,.
    Country: USA
    Angiology. 2018 Jan 1:3319718780772
  • “The CT-1/Gal-3 axis emerges as a candidate therapeutic target and a potential prognostic biomarker in HF".
    Martinez-Martinez E.
    Hypertension. 2019 Jan 7
    Country: Spain

Contact Us

Send us an email if you have questions about our study and plans.

Send Message
UA-108139300-1

Contact us or Follow us on Twitter

© 2025 · G3 pharmaceuticals Inc.